NCT02635061终止1 期
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Celgene
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- recommended Phase 2 dose (RP2D) of ACY 241 in combination with nivolumab
研究概览
简要总结
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be able to understand and voluntarily sign an informed consent form (ICF).
- •Must be ≥ 18 years of age at the time of signing the ICF.
- •Must be able to adhere to the study visit schedule and other protocol requirements.
- •Patients must have histologically confirmed unresectable NSCLC for which nivolumab is clinically appropriate. Patients must have had one line of prior therapy and have progressed or have discontinued due to toxicity.
- •Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).
- •Life expectancy > 12 weeks.
- •Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or
- •Willingness to have pre treatment and on treatment tumor biopsies.
- •Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female patients of childbearing potential must agree to use adequate contraceptive measures until 3 months after the last study drug is taken. Females of childbearing potential must have a negative pregnancy test. It is not known if the antideacetylase activity of this experimental drug may be harmful to the developing fetus or nursing infant.
- •Male patients should be willing to use barrier contraceptive (ie, condoms) until 3 months after last study drug is taken.
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from giving informed consent.
- •Any serious concurrent medical conditions, laboratory abnormality, or psychiatric illness that might make the patient nonevaluable, put the patient's safety at risk, or prevent the patient from following the study requirements.
- •Pregnant or lactating females.
- •Patients with uncontrolled brain metastases. Existing brain metastases must have been previously treated and currently stable.
- •Patients who have had chemotherapy within 14 days before entering the study or those who have not recovered from AEs to ≤ Grade 1 due to agents administered more than 14 days earlier.
- •Previous therapy with histone deacetylase (HDAC) inhibitor and/or anti PD 1, anti PD L1, or anti CTLA4 immunotherapy.
- •Any of the following laboratory abnormalities:
- •ANC < 1,500/µL
- •Platelet count < 100,000/µL
- •Hematologic growth factors are not allowed at Screening or during the first cycle of treatment
- •Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell transfusion is permitted)
- •Creatinine > 1.5 × upper limit of normal (ULN)
- •AST or ALT > 2.5 × ULN. For patients with liver metastasis AST or ALT > 5 × ULN
- •Serum total bilirubin > 1.5 mg/dL or > 3 × ULN for patients with hereditary benign hyperbilirubinemia
- •Corrected QT interval (QTc) using Fridericia's formula (QTcF) value > 480 msec at Screening; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy at Screening; previous history of drug induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram (ECG).
- •Congestive heart failure (New York Heart Association Class III or IV), myocardial infarction within 12 months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
- •Patients with chronic autoimmune disease(s) requiring systemic immunosuppression.
- •Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
- •Patients who received any of the following within the 14 days before initiating study treatment: major surgery, radiation therapy, and/or systemic therapy (standard or an investigational or biological anticancer agent).
- •Current enrollment in another clinical study involving treatment and/or is receiving an investigational agent for any reason, or use of any investigational agents within 14 days of initiating study treatment.
- •Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.
研究组 & 干预措施
ACY-241 in combination with nivolumab
Experimental
干预措施: ACY-241 (Drug)
ACY-241 in combination with nivolumab
Experimental
干预措施: Nivolumab (Drug)
结局指标
主要结局
recommended Phase 2 dose (RP2D) of ACY 241 in combination with nivolumab
时间窗: one to two years
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: one to two years
次要结局
- preliminary antitumor activity of ACY 241 in combination with nivolumab(one to two years)
- Maximum Plasma Concentration [Cmax] of ACY 241 in combination with nivolumab on biomarkers in peripheral blood and tumor tissue(one to two years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabMalignant MelanomaNCT02935790Celgene1
撤回
2 期
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract CancerBiliary Tract CancerNCT04186156Karus Therapeutics Limited
终止
1 期
ACY-1215 for Relapsed/Refractory Lymphoid MalignanciesLymphoid MalignanciesLymphomaNCT02091063Jennifer Amengual23
终止
2 期
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic LymphomaSLLChronic Lymphocytic LeukemiaCLLNCT02046928Ångstrom Pharmaceuticals5
已完成
1 期
The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy SubjectsHealthyNCT03655873Sunshine Lake Pharma Co., Ltd.43